In the BioHarmony Drug Report Database

"Preview" Icon

Ixazomib

Ninlaro (ixazomib) is a small molecule pharmaceutical. Ixazomib was first approved as Ninlaro on 2015-11-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. In addition, it is known to target proteasome subunit alpha type-7. Ninlaro’s patents are valid until 2029-11-20 (FDA).

 

Trade Name

 

Ninlaro
 

Common Name

 

ixazomib
 

ChEMBL ID

 

CHEMBL2141296
 

Indication

 

multiple myeloma
 

Drug Class

 

Proteozome inhibitors

Image (chem structure or protein)

Ixazomib structure rendering